| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/15-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | CA125 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human MUC16 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MUC16抗体的3篇代表性文献摘要(虚拟示例，非真实文献)：
1. **文献名称**：*Development of a novel anti-MUC16 antibody for targeted ovarian cancer therapy*
**作者**：Smith A, et al.
**摘要**：研究团队开发了一种高亲和力单克隆抗体(命名为AB-MUC16)，可特异性结合MUC16的串联重复表位。实验显示该抗体在卵巢癌异种移植模型中显著抑制肿瘤生长，并增强化疗药物递送效率。
2. **文献名称**：*MUC16 antibody-based liquid biopsy for early detection of pancreatic cancer*
**作者**：Chen L, et al.
**摘要**：利用MUC16抗体构建了新型血清外泌体检测技术，通过识别MUC16胞外脱落片段，实现了胰腺癌早期诊断(灵敏度92%，特异性85%)，比传统CA-125检测更精准。
3. **文献名称**：*Structural insights into MUC16-antibody interactions reveal potential therapeutic targets*
**作者**：Wang Y, et al.
**摘要**：通过冷冻电镜解析了MUC16胞外域与治疗性抗体的复合物结构，发现了一个新的构象依赖性表位，为设计双特异性抗体及克服MUC16糖基化异质性提供了理论依据。
---
*注：以上为模拟内容，实际文献需通过PubMed/Google Scholar检索关键词"MUC16 antibody"、"CA-125 therapeutic"等获取。如需真实文献推荐可提供具体研究方向。*
MUC16. a large transmembrane glycoprotein belonging to the mucin family, is characterized by its extensive glycosylation and tandem repeat domains. It plays a critical role in cellular lubrication, signaling, and immune modulation. Clinically, MUC16 is best known as the antigen recognized by the cancer biomarker CA125. widely used for monitoring ovarian cancer progression and treatment response. Overexpression of MUC16 is strongly associated with malignancies, including ovarian, pancreatic, and breast cancers, where it promotes metastasis, immune evasion, and chemoresistance by interacting with mesothelin and galectins.
Antibodies targeting MUC16 have become essential tools in diagnostics and therapeutics. In diagnostics, anti-MUC16 antibodies underpin CA125-based immunoassays for cancer screening and recurrence detection. Therapeutically, engineered monoclonal antibodies (e.g., oregovomab), antibody-drug conjugates (ADCs), and CAR-T cells targeting MUC16 are under investigation. These therapies aim to disrupt tumorigenic pathways or deliver cytotoxic payloads specifically to MUC16-expressing cancer cells.
However, challenges remain due to MUC16's structural complexity, glycosylation heterogeneity, and potential shedding of extracellular domains, which may compromise antibody specificity and efficacy. Ongoing research focuses on optimizing epitope selection, enhancing antibody penetration, and overcoming immune tolerance. Advances in bispecific antibodies and combination therapies hold promise for improving outcomes in MUC16-associated cancers.
×
